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Abstract
Cocaine is a stimulant that leads to the rapid
accumulation of catecholamines and serotonin in the
brain due to prevention of their re-uptake into the
neuron that released the neurotransmitter. Cocaine
dependence is a public health concern and cause of
significant morbidity and mortality worldwide. At
present, there are no approved medications for the
treatment of this devastating illness, and behavioral
interventions have proven to be of limited use.
However, there have been a number of recent trials
testing promising agents including dopamine
agonists, GABAergic medications and the cocaine
vaccine. Here we discuss the most recent human
clinical trials of potential medications for treatment of
cocaine dependence, as well as pre-clinical studies for
another promising agent, levo tetrahydropalmatine.
Examination of these recent findings shows promise
for GABAergic medications and the cocaine vaccine,
as well as unique medications such as disulfiram,
whose mechanism remains to be determined. Future
work may also confirm specific subgroups of patients
for treatment response based on clinical
characteristics, biomarkers and pharmacogenetics. This
review highlights the need for further, bigger studies
in order to determine optimal clinical usage.
Introduction
Cocaine is a stimulant that leads to the rapid accumulation
of catecholamines and serotonin in the brain due to pre-
vention of their re-uptake into the neuron that released
the neurotransmitter. Cocaine use disorders are widely
accepted as a significant cause of morbidity and mortality.
Cocaine use is associated with numerous acute and
chronic medical complications, ranging from coronary
syndromes, myocardial infarction, and respiratory disease
to neurologic and psychiatric consequences such as cere-
bral hemorrhage, mood disorders, and psychosis [1,2].
Additionally, cocaine use has been associated with
increased risk of HIV, hepatitis B and C, and violence
[3-6].
Development of effective treatments for cocaine depen-
dence is necessary to reduce the impact of this illness
upon both the individual and society. These effective
treatments need most importantly to reduce cocaine use
and to have excellent compliance, which has encouraged
depot and other long lasting formulations. Currently,
however, there are no US Food and Drug Administration
(FDA) approved medications for the treatment of this ill-
ness, and behavioral therapies alone have demonstrated
limited efficacy [7]. Our growing understanding of
cocaine neurobiology has translated into numerous
studies of pharmacologic agents for treatment of cocaine
dependence in both animal and human models. These
models include human laboratory drug administration
studies using surrogate endpoints such as craving,
subjective effects, and behavioral choices of money versus
drug. This article reviews findings from recent cocaine
pharmacotherapy clinical trials in humans that target
dopamine and gamma-aminobutyric acid (GABA) neuro-
transmitter systems or uniquely target the cocaine itself
through a vaccine preventing cocaine from getting into
the brain. Additionally, preclinical studies for a novel
medication, levo-tetrahydropalmatine (l-THP) are
discussed.
Dopamine agonists
The final common pathway for reward and reinforcement
associated with substances of abuse has been extensively
shown to result from dopamine release from the ventral
tegmental area (VTA) to the nucleus accumbens (NAc),
prefrontal cortex (PFC), as well as other structures [8].
The subjective effects and euphoria of cocaine use are
attributed to blockade of the dopamine transporter, reup-
take inhibition, and increased levels of extracellular
* Correspondence: shorter@bcm.edu
1Menninger Department of Psychiatry and Behavioral Science, Baylor College
of Medicine, 1977 Butler Blvd., Suite E4.400, Houston, TX 77030, USA
Full list of author information is available at the end of the article
Shorter and Kosten BMC Medicine 2011, 9:119
http://www.biomedcentral.com/1741-7015/9/119
© 2011 Shorter and Kosten; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.dopamine in the mesolimbic and mesocortical pathways.
Chronic use of cocaine is associated with relative dopami-
nergic hypofunctioning and may underlie the withdrawal
symptoms and craving observed in cocaine-dependent
persons who have recently established abstinence [9]. As a
result, dopamine agonists have been studied as potential
pharmacotherapeutic options, since they serve to offset
neuroadaptive changes associated with chronic use such as
decreased dopamine D2 receptor binding [10] and have
been used successfully for the treatment of both opiate
and nicotine dependence, highlighting their potential uti-
lity for treatment of other forms of substance abuse
[11,12]. Recent trials for dopamine agonists have mainly
focused on amphetamine derivatives such as dextroam-
phetamine (d-amphetamine) and methamphetamine, as
well as modafinil and disulfiram.
D-amphetamine has shown mixed results in regards to
its ability to attenuate subjective effects [13,14]. In clini-
cal study oral methamphetamine demonstrated an ability
to reduce both craving and cocaine use, as evidenced by
a statistically significant increase in the percentage of
cocaine-negative urines [15]. Concerns regarding the
addictive liability of these agents in persons with a history
of substance dependence remain a consideration, particu-
larly since the dependence syndrome (characterized by
development of tolerance, withdrawal, and inability to
control use) has been clearly established for ampheta-
mines [16]. Overall, slow release formulations with strong
diversion resistant formulations would be essential for
use of amphetamine as a treatment agent. So far, no such
formulation has been developed although a lysine conju-
gate of amphetamine that has been marketed for treating
childhood attention deficit disorder shows some promise.
However, these medications have shown some promise
and merit further clinical investigation, particularly as
cognitive enhancement during early abstinence becomes
a more prominent focus in addictions research and these
agents may also be helpful in this area.
Modafinil is a novel stimulant-like medication that pro-
motes wakefulness and serves as a treatment for hypersom-
nia and narcolepsy. The mechanism of action is only
partially understood at this time; however, there is evidence
that this agent acts as a central alpha-1 adrenergic agonist
[17], reduces basal cerebral GABA activity [18], and
increases both dopamine and glutamate release in select
areas of the brain [19,20]. Chronic cocaine use results in a
hypodopaminergic state as well as depletion of both extra-
cellular glutamate levels and glutamatergic synaptic
strength in the nucleus accumbens [21]. These neurotrans-
mitter systems serve as the principal targets of modafinil’s
effects and promising results in human clinical trials for
treatment of cocaine dependence have been observed.
The safety of co-administration of modafinil and
cocaine was established in a randomized, double blind,
placebo-controlled study (N = 10) conducted by Dackis
et al. [22]. Modafinil demonstrated no significant exacer-
bating effects on vital sign measures or electrocardiogram
(EKG) findings. As a secondary measure, pretreatment
with modafinil at two oral dosages (200 mg and 400 mg,
respectively) demonstrated an ability to significantly
attenuate euphoria from intravenously administered
cocaine in one subjective measure (P = 0.02). Impor-
tantly, this early study suggested safety as well as the pos-
sibility of a cocaine-blunting effect with modafinil.
In addition to examining the impact of modafinil on the
euphorigenic effects of cocaine, early research focused on
the similarity of modafinil to stimulant medications in
order to assess the extent of its potential abuse liability in
both humans and animals [23,24]. Overall, the perceived
risk of abuse associated with this medication has been
found to be limited, since modafinil possesses, at most, a
weakly reinforcing effect [24]. More recently, a double-
blind, randomized, outpatient study (N = 12) conducted in
cocaine addicted subjects found that modafinil at three
different doses (200 mg, 400 mg, and 600 mg/day, respec-
tively) failed to elicit a reinforcing effect, as the medication
was chosen at the same frequency as placebo and was not
associated with positive subjective effects [25].
Recent clinical trials of modafinil in human subjects
have highlighted either (1) the medication’s impact upon
actual cocaine use or (2) its ability to mitigate symptoms
associated with cocaine abstinence. The rationale for
using this medication relates to its stimulant like proper-
ties and potential efficacy as a substitution agent that can
reduce craving for cocaine. With regard to its effect upon
cocaine use, modafinil was examined in a randomized,
double-blind, placebo-controlled study (N = 210) at two
doses (200 mg and 400 mg); however, no significant dif-
ferences were observed between the modafinil and pla-
cebo groups in their change in the average weekly
percentage of cocaine non-use days [26]. Of note, moda-
finil 200 mg demonstrated a significant reduction in crav-
ing as a secondary outcome. Interestingly, post-hoc
analysis also found an increase in cocaine non-use days
among those with co-morbid alcohol dependence who
were treated with modafinil, suggesting a possible target
subgroup among cocaine-addicted persons.
The impact of modafinil on sleep in chronic cocaine
users was examined in a randomized, placebo-controlled,
inpatient study (N = 20) by Morgan et al. The research-
ers found that modafanil 400 mg decreased nighttime
sleep latency and increased slow-wave sleep time [27].
Additionally, by the third week of abstinence from
cocaine, the modafinil group experienced longer total
sleep time and shorter rapid eye movement (REM)
latency. Ultimately, modafanil demonstrated a normaliz-
ing effect on sleep, which could be particularly important
during early phases of abstinence since sleep disturbance
Shorter and Kosten BMC Medicine 2011, 9:119
http://www.biomedcentral.com/1741-7015/9/119
Page 2 of 9has been associated with relapse into substance abuse
and there are currently no proven pharmacologic treat-
ment options for this form of insomnia [28]. Modafinil
continues to represent an area of exciting promise in the
pharmacologic management of cocaine dependence,
since it appears to have limited reinforcing effects,
reduces cocaine craving, decreases cocaine use among
sub-populations of cocaine users (that is, those with co-
morbid alcohol dependence), and treats symptoms char-
acteristic of the abstinence syndrome.
Disulfiram, an aldehyde dehydrogenase inhibitor as
well as a dopamine-beta-hydroxylase (DBH) inhibitor, is
approved for treatment of alcohol dependence. Because
the DBH enzyme converts dopamine to norepinephrine,
its inhibition leads to a decrease in neuronal and synaptic
norepinephrine levels relative to dopamine [29]. This
neurobiochemical mechanism has been proposed as a
potential therapy for cocaine dependence, extensively
studied in human clinical trials, and found to result in
modulation of the reinforcing properties of cocaine and
reduction of cocaine use [30-32]. Most recently, a dou-
ble-blind, placebo-controlled randomized clinical trial
(RCT) of disulfiram for treatment of cocaine dependence
in methadone-stabilized individuals showed that in the
group receiving 250 mg/day, there was a significant
decrease in cocaine-positive urines over time when com-
pared to lower doses of the medication or placebo [33].
Interestingly, lower dosages of the medication (62.5 mg
and 125 mg, respectively) were associated with increased
self-report of cocaine use as well as cocaine-positive
urines. Future study of disulfiram should focus on dosing
strategy as well as identification of subpopulations in
which the drug is maximally effective.
Nepicastat, a selective DBH-inhibitor that has yet to
come to market, is currently under investigation for
treatment of cocaine dependence. In preclinical trials,
nepicastat has demonstrated an ability to (1) increase
synaptic levels of dopamine, (2) decrease brain norepi-
nephrine levels, and (3) block cocaine-induced reinstate-
ment of cocaine seeking in rats without affecting food-
primed reinstatement of food seeking [34]. These results
suggest similarity between disulfiram and nepicastat in
terms of their ability to attenuate responses to drug-
related cues and represent an exciting prospect in the
pharmacotherapy of cocaine dependence.
Serotonergic agents
In addition to its action at the dopamine transporter,
cocaine binds to the norepinephrine transporter (NET)
and serotonin transporter (SERT), causing inhibition of
presynaptic uptake of these monoamines as well [35].
During acute cocaine intoxication, enhanced dopamine
transmission in the nucleus accumbens is accompanied
by increased release of serotonin [36], and there is
evidence supporting the contributing role of serotonin to
cocaine reward and reinforcement [37]. In the dorsal
raphe nucleus, increased extracellular levels of serotonin
result in activation of 5-hydroxytryptamine-1a (5HT-1a)
autoreceptors and reduce firing of these neurons [38].
Cocaine withdrawal is characterized by serotonin deple-
tion throughout the brain and decreased levels of 5HT in
the nucleus accumbens [39]. Interestingly, in rat studies,
enhancement of serotonergic transmission in the nucleus
accumbens through administration of exogenous 5HT
served to offset the dopamine deficit caused by cocaine
withdrawal [40].
Given these interactions, preclinical studies have exam-
ined the impact of pharmacologic manipulation of the
serotonin system on cocaine effects. Early studies in rats
demonstrated that serotonin-enhancing medications
were associated with decreased self-administration of
cocaine [41,42]. However, human clinical trials examin-
ing the efficacy of serotonergic medications (that is,
selective serotonin reuptake inhibitors (SSRI)) in the
treatment of cocaine dependence have yielded mixed
results [43-46].
The discrepancy between findings from animal and
human trials regarding the effect of serotonergic medica-
tions might be due to differences in the circumstances
leading to reinstatement of cocaine use. In a review by
Filip et al., the authors stress that activity at different
subtypes of serotonin receptors can have different effects
on cocaine use. For example, cocaine-seeking behavior
induced by environmental cues (conditioned stimuli) can
be modified by serotonergic medications that counteract
the 5HT deficit of withdrawal or suppress cocaine-
induced changes in this neurotransmitter system [47].
Moeller et al. tested this particular hypothesis in a
recent double-blind, placebo-controlled RCT (N = 76)
examining citalopram (20 mg/day) combined with cogni-
tive behavioral therapy (CBT) and contingency manage-
ment (CM) over 12 weeks in the treatment of cocaine
dependence [48]. The subjects in the citalopram group
demonstrated a substantial decrease in the number and
probability of cocaine positive urine drug screens. As a
future direction, the use of behavioral therapy platforms
to address response to drug-related cues in conjunction
with serotonergic agents may be the necessary adjunct to
treatment to improve the efficacy of these medications.
Ibogaine, the primary indole alkaloid found in the root
bark of the African shrub, Tabernanthe iboga, has shown
promise not only in the treatment of cocaine dependence,
but in alcohol, opiate, and methamphetamine dependence
as well, representing the first agent that could be beneficial
in multiple substance use disorders (SUDs) [49]. The phar-
macologic properties of ibogaine have been extensively
studied and ibogaine has demonstrated an affinity for a
number of receptor sites including opioid (kappa, mu, and
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dopamine transporter (DAT), SERT, and nicotinic [50].
The action of this medication at multiple receptor sites in
combination has been identified as the predominant factor
underlying the putative anti-addictive properties of ibo-
gaine. However, despite general agreement on the sites of
activity of this medication, there remain some contradic-
tory findings in regards to the action of ibogaine within
the brain. For example, Baumann et al found that ibogaine
and noribogaine had little effect on extracellular levels of
dopamine in the rat nucleus accumbens, while Glick et al.
showed that these agents caused a significant decrease in
dopamine levels [51,52]. These differences may be due to
differences in study design, method of administration of
ibogaine and/or the gender of the animals. In regards to
serotonergic transmission, both ibogaine and noribogaine
have been shown to increase extracellular 5HT in the
brain [52].
Regarding its impact on cocaine use, both ibogaine and
its active metabolite, noribogaine, have been shown to
significantly decrease cocaine self-administration, an
effect that persisted in some animals for several days fol-
lowing only a single dose [53]. Although ibogaine is asso-
ciated with potentially intolerable side effects, such as
tremor and impaired coordination, noribogaine does not
appear to cause these problems, suggesting this agent
may be easier to tolerate [51].
One focus in clinical trials has been to isolate specific
iboga alkaloids, such as 18-methoxycoronaridine (18-
MC), in order to test their efficacy in treating chemical
dependency with minimal adverse reactions [54]. Impor-
tantly, 18-MC has demonstrated an ability to reduce
cocaine self administration without apparent toxicity
[55]. Of note, 18-MC has also shown an ability to reduce
self administration of other drugs of abuse, including
morphine, methamphetamine, nicotine, and alcohol [54].
To date, there have been no human clinical trials for
treatment of cocaine dependence with iboga alkaloids;
however, this class of medications, with enhanced safety
profiles, could represent an exciting intervention in the
treatment of not only cocaine dependence, but other
drug use disorders as well.
GABA-ergic medications
There is significant evidence for the involvement of brain
GABA systems in perpetuation of the addictive process
and the enhancement of GABA activity in addicted indi-
viduals is associated with decrease in drug craving and
relapse [56]. More specifically, GABA has demonstrated
the ability to suppress dopamine release in the striatum,
also blunting cocaine-induced release of dopamine in
animals. The translation of our understanding of this
neurobiology into successful human clinical trials has
been somewhat difficult. An additional complicating
factor with this class of medications is that given the
widespread distribution of the GABAergic system within
the central nervous system (CNS), these medications may
be associated with various side effects. Recent studies of
vigabatrin, baclofen, valproate, and topiramate yield
mixed results in their ability to improve outcomes in
cocaine-addicted persons.
Vigabatrin, also known as gamma-vinyl-GABA (GVG),
is an irreversible inhibitor of GABA transaminase that
reduces the breakdown of GABA, thereby increasing its
activity within the synapse [56]. In preclinical studies GVG
has been shown to reduce cocaine-induced dopamine
release by 25% or more in laboratory animals; however,
there has also been an association with visual field defects
in 1/3 of persons exposed to the medication for extended
periods [57]. In a recently published RCT (N = 103),
GVG, when compared to placebo, resulted in a higher per-
centage of subjects achieving and maintaining abstinence
from cocaine by the end of the trial (20% of GVG group
(n = 50) versus 7.5% of placebo (n = 53)) [58]. Interest-
ingly, participants in the GVG group were also more likely
to report abstinence from alcohol by the end of study
(43.5% versus 6.3%). Study retention was significantly
higher in the GVG group and the medication was well tol-
erated. Ongoing study of GVG is necessary, particularly
given its potential implications for the subpopulation of
patients with cocaine dependence and comorbid alcohol
abuse/dependence.
Baclofen, a GABA(B) receptor agonist, is used widely as
a treatment of spasticity and has demonstrated efficacy in
preclinical trials for treatment of cocaine dependence. In
various rat studies, baclofen demonstrated the ability to
reduce cocaine self-administration [59,60] and cocaine-
induced reinstatement [61], cocaine-seeking behaviors
[62], and cocaine-induced release of dopamine (DA) in
the shell of the nucleus accumbens [63].
In an earlier double blind, placebo-controlled RCT (N =
70), Shoptaw et al. found that administration of baclofen
(20 mg three times a day) resulted in statistically signifi-
cant reductions in cocaine use when compared to placebo
[64]. Although baclofen did not demonstrate a statistically
significant impact on cocaine craving, participants were
more likely to submit cocaine-negative urine samples
between weeks three to eight of treatment. This finding
may suggest the possible utility of this medication in those
needing assistance with relapse prevention, rather than
abstinence initiation. Of note, the authors also examined
the impact of the level of cocaine use at baseline on treat-
ment outcome, finding that those with a more severe form
o fc o c a i n ed e p e n d e n c ew e r em o r el i k e l yt or e s p o n dt o
baclofen treatment. A more recent multisite, double-blind
RCT assessed the safety and efficacy of 60 mg baclofen
treatment for in 160 subjects diagnosed with severe
cocaine dependence [65]. The groups (treatment versus
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rates or change in mean weekly percentage of cocaine
non-use days. The limited success of baclofen may be due
to its use in a population identified as severely cocaine
dependent or because it was used to assist with abstinence
initiation, rather than relapse prevention. Examination of
baclofen in subjects with mild to moderate cocaine depen-
dence or in those who have already established abstinence
may yield more promising results.
Valproate, which enhances GABA levels by increasing
glutamic acid decarboxylase (GAD) activity and inhibiting
GABA transaminase activity, was examined in a RCT,
within-subjects, crossover study design meant to assess its
effect on cue-induced cocaine craving [66]. Subjects iden-
tified as crack cocaine dependent (N = 20) were titrated to
1, 500 mg/day of valproate and subsequently exposed to a
series of neutral and cocaine-related cues. Interestingly,
under treatment conditions with valproate, participants
reported higher craving (that is, ‘desire to use now’)i n
response to cue exposure when compared to placebo con-
dition. Due to limited sample size, however, further study
of this medication may still be warranted.
Tiagabine, a GABA reuptake inhibitor, has been exam-
ined in two recent human clinical trials. In an earlier
RCT (N = 141), the group receiving tiagabine (20 mg/
day) did not differ significantly from placebo in terms of
cocaine craving and global function [67]. Additionally,
there was no significant change in cocaine use in either
the study or placebo groups. A later study compared the
impact of tiagabine versus lorazepam, a benzodiazepine
and GABA-enhancing medication, and placebo. The
authors found that tiagabine increased slow-wave sleep
by three times in those recently establishing abstinence
from cocaine use [68]. Importantly, tiagabine did not dif-
fer from placebo in regards to impact on cognitive func-
tion (that is, vigilance task, measures of impulsivity),
while lorazepam was found to cause next-day impair-
ment. There may be a possible indication for tiagabine in
the period of early abstinence, since this medication
might improve the sleep disturbance characteristic of
withdrawal; however, additional study is warranted to
determine the extent of its effect upon establishment of
abstinence, cocaine craving, and relapse.
The final GABAergic medication to have been recently
tested in human clinical study is topiramate which, in
addition to potentiation of GABA(A) receptor mediated
input, antagonizes glutamatergic afferents to the meso-
corticolimbic dopaminergic system [69]. Kampman et al.
demonstrated the efficacy of topiramate in the treatment
of cocaine dependence in a randomized, double-blind,
placebo-controlled RCT (N = 40) [70]. Over the first
eight weeks of the study, topiramate was titrated by 25
mg/week to a target dose of 200 mg/day. During that
period, topiramate did not demonstrate a statistically
significant ability to reduce cocaine use. After week eight,
topiramate-treated subjects were more likely to be absti-
nent from cocaine when compared to placebo, as mea-
sured by twice-weekly urine benzoylecgonine test (UBT).
In an open label, outpatient study of cocaine depen-
dent men (N = 28), participants received topiramate,
ranging in dose from 25 to 300 mg/day [71]. Interest-
ingly, the only statistically significant finding of the
study was a decrease in craving intensity, although this
effect was seen in only 25% of participants. Further
study of topiramate in a larger, placebo-controlled RCT
is necessary in order to determine the extent of this
medication’s impact upon craving. Also, the addition of
genetic analysis into future trials might help to deter-
mine underlying differences in subgroups of patients
and provide clues regarding differential response
patterns.
Levo-tetrahydropalmatine
Levo-tetrahydropalmatine (l-THP), a tetrahydroprotober-
berine alkaloid, is one of the primary active agents found
in the plant genera Corydalis and Stephania [72]. Two
species in particular, Corydalis ambiguo and Stephania
tetranda, are included among the 50 fundamental herbs
in Chinese traditional medicine and are used for various
purposes including treatment of anxious insomnia and
chronic pain due to their sedative/hypnotic and analgesic
properties, respectively [72,73]. The mechanism of action
of l-THP, elucidated by studies in rats, centers around
antagonism of dopamine D1 and D2 receptors [74] and
was further evidenced by its ability to reverse the effects
of apomorphine, a known dopamine receptor agonist
[75]. Additionally, there is evidence to suggest antagonist
activity at D3 receptor sites [72]. In addition to activity in
the dopaminergic system, l-THP has shown an ability to
act as both an alpha-1 adrenergic receptor antagonist
(Mantsch, 2007) and an allosteric modulator of gamma-
aminobutyric acid (GABA)A receptors [76]. Interestingly,
this agent has a similar effect to modafinil, but acts
through a different mechanism.
Taken altogether, the unique neurobiochemical profile
of l-THP may translate into an exciting area of promise
in the study of pharmacotherapy for cocaine depen-
dence. In rats, l-THP has demonstrated an ability to
dose-dependently reduce cocaine self-administration and
attenuate cocaine-induced reinstatement under both
fixed-ratio [72] and progressive-ratio scheduling [77].
Further, oral administration of l-THP was found to
attenuate cocaine-seeking behavior within various rein-
statement paradigms (that is, cocaine, stress, and envir-
onmental associated cues) [78]. These findings in animal
studies suggest that l-THP may represent an effective
future pharmacotherapeutic option in the treatment of
cocaine dependence.
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Substance abuse vaccines represent an exciting area of
promise in the treatment of chemical dependency. The
introduction of these agents into our pharmacologic arma-
mentarium represents an important shift in our concep-
tualization of drug use, since its foundation rests upon the
idea of substances of abuse as agents ‘foreign’ to the body
and susceptible to immunologic mechanisms. Currently,
clinical trials for vaccines treating both cocaine and nico-
tine dependence are ongoing, with vaccines for metham-
phetamine and heroin in preclinical development stages.
The cocaine vaccine, TA-CD, is composed of a cocaine
hapten conjugated to inactivated cholera toxin B, resulting
in the creation of a molecule capable of stimulating an
antibody response [79]. These antibodies are cocaine spe-
cific; ingestion of the substance by any means (intranasal,
inhalational, intravenous) results in its binding and the
creation of immune complexes unable to cross the blood-
brain-barrier due to their relatively larger size. These
molecules are then broken down by cholinesterases in the
circulation, converting the cocaine into inactive metabo-
lites that are then excreted [80].
In phase I clinical study (N = 34), participants receiving
TA-CD were able to mount an immunologic response
resulting in the creation of cocaine-specific antibodies
[81]. Subjects reported a reduction in the subjective effects
and euphoria from smoked cocaine [82,83].
Similarly positive findings were found during a phase II
clinical study of two dose levels (100 ug × 4 injections, or
400 ug × 5 injections)[82]. Subjects receiving the higher
dose were found to have higher mean antibody levels and
were also more likely to remain abstinent at six-month
follow-up (relapse in 89% in the low-dose group com-
pared to 43% in the high-dose group) [82,80].
In the initial phase IIb trial (N = 115), TA-CD was
administered to methadone-maintained cocaine-depen-
dent individuals at a single dose (360 ug × 5 injections)
in comparison to placebo. Those subjects with high anti-
body production were found to have a greater percentage
of cocaine-free urines [84]. In all phases of testing, the
safety profile of the vaccine was favorable, with any ser-
ious adverse effects being deemed unrelated to the vac-
cine. Currently, TA-CD is undergoing large-scale,
multisite, phase IIb clinical testing, although there are
limitations in these studies including only 40% of the
patients attaining fully blocking levels of antibodies. Bet-
ter adjuvants are clearly needed.
Summary/Future directions of research
These prospects in the pharmacologic management of
cocaine dependence have demonstrated in human clini-
cal trials an ability to reduce subjective reward, craving,
and withdrawal symptoms associated with cocaine use,
however, there is still much progress to be made, before
they are viable widespread treatments Of the dopamine
agonist medications, although they have been demon-
strated to decrease the euphoric, as well as, in some
cases, the withdrawal symptoms, concerns regarding
the addictive liability of amphetamine-type medications
continue to limit the widespread acceptance and use of
this treatment. Further, findings in clinical trials of
GABAergic medications have been less clear in their
demonstration of significant efficacy in treating cocaine
dependence. They have shown some ability to reduce
cocaine craving or to improve sleep duration and quality
in those recently abstaining from cocaine, and cocaine
abusers with comorbid alcohol dependence may repre-
sent a subpopulation particularly responsive to the effects
of GVG. The cocaine vaccine, TA-CD, has demonstrated
the ability to elicit an immunologic response capable of
reducing the subjective reward of cocaine use in both
animals and humans. These results make immunologic
treatment of substance use disorders an exciting direc-
tion for treatment of not only cocaine dependence, but
other substances as well. Finally, findings from preclinical
trials for l-THP suggest this medication, already used for
centuries as an herbal medication for other disorders,
may be helpful in reducing cocaine use.
Conclusions
Examination of these recent findings shows promise for
GABAergic medications and the cocaine vaccine, as well
as for unique medications such as disulfiram, whose
mechanism remains to be determined. Further studies
with all of these agents are likely to be worthwhile,
although the focus for disulfiram needs to be on its poten-
tial mechanism of action such as its inhibition of dopa-
mine beta hydroxylase using more specific agents like
nepicastat. Alternatively, the copper chelation caused by
disulfiram is being examined using more specific copper
chelating compounds that have been developed for Wil-
son’s disease. Alternative agents with fewer side effects are
being examined for vigabitrin. Finally, more effective
vaccines have been developed in animals using better adju-
vants than alum such as squalene or MPL60 as alterna-
tives. Clearly progress has been made in developing new
and unique agents and mechanisms of action for reducing
cocaine dependence. Specific barriers to developing better
treatments are clearly related to the overall challenges of
getting industry support and FDA approval when no pre-
vious medication has been approved for cocaine depen-
dence. Small companies are working well with the US
National Institute on Drug Abuse (NIDA) to develop
these therapies, but the larger pharmaceutical industry will
be essential partners for the FDA process in bringing any
of these treatments to market. Some aspects of cocaine
addiction need to be better understood in order to make
further progress. In particular, the mechanisms of action
Shorter and Kosten BMC Medicine 2011, 9:119
http://www.biomedcentral.com/1741-7015/9/119
Page 6 of 9relevant to disulfiram’s efficacy for cocaine need to be
identified in order to develop better, safer, and more speci-
fic agents. Furthermore, it is likely that treatment will need
to be more tailored for specific subsets of patients. These
subsets may be identified through clinical characteristics
(severity of dependence based on number of days of
month of using cocaine), biomarkers (urine levels of the
cocaine metabolite benzoylecognine or having immuno-
globulin M (IgM) antibodies to cocaine before first vaccine
dose) and pharmacogenetic markers
(functional polymorphisms associated with the gene
coding for dopamine beta hydroxylase),
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